Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Reaffirmed by Cantor Fitzgerald

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday.

Abeona Therapeutics Price Performance

NASDAQ ABEO opened at $3.17 on Tuesday. The business has a fifty day moving average price of $7.43 and a two-hundred day moving average price of $5.65. Abeona Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $9.01. The stock has a market capitalization of $86.70 million, a PE ratio of -1.23 and a beta of 1.49.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). As a group, sell-side analysts expect that Abeona Therapeutics will post -1.83 earnings per share for the current year.

Institutional Trading of Abeona Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ABEO. Adage Capital Partners GP L.L.C. grew its holdings in Abeona Therapeutics by 84.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock worth $13,682,000 after acquiring an additional 1,488,834 shares during the period. AIGH Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 77.7% in the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after buying an additional 496,278 shares during the last quarter. Citigroup Inc. lifted its stake in Abeona Therapeutics by 125.0% in the third quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock valued at $1,894,000 after purchasing an additional 250,000 shares during the last quarter. Barclays PLC raised its holdings in Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after acquiring an additional 185,638 shares during the period. Finally, Worth Venture Partners LLC raised its holdings in Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after acquiring an additional 121,969 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.